Cargando…

Chimeric antigen receptors in the brain: Can we tackle glioblastoma with engineered NK cells?

Detalles Bibliográficos
Autor principal:	Roth, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628930/ https://www.ncbi.nlm.nih.gov/pubmed/37522296 http://dx.doi.org/10.1093/neuonc/noad131

Ejemplares similares

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
por: Burger, Michael C, et al.
Publicado: (2023)

Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
por: Hänsch, Lena, et al.
Publicado: (2023)

Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
por: Stoecklein, Sophia, et al.
Publicado: (2023)

Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
por: Marei, Hany E., et al.
Publicado: (2021)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
por: Wang, Xiao, et al.
Publicado: (2022)

Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy
por: Nakagawa, Tomoyoshi, et al.
Publicado: (2022)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020)

Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
por: Kim, Nayoung, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
por: Elahi, Reza, et al.
Publicado: (2021)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018)

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
por: Land, Craig A., et al.
Publicado: (2020)

Current and future perspectives of chimeric antigen receptors against glioblastoma
por: Zhang, Josephine, et al.
Publicado: (2022)

Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
por: Schmidts, Andrea, et al.
Publicado: (2022)

Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review
por: Banerjee, Rahul, et al.
Publicado: (2021)

An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer
por: Badoual, Cécile, et al.
Publicado: (2013)

Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future
por: Kringel, Rebecca, et al.
Publicado: (2023)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Chimeric antigen receptor–engineered T cells as oncolytic virus carriers
por: VanSeggelen, Heather, et al.
Publicado: (2015)

Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
por: Gavriil, Artemis, et al.
Publicado: (2020)

The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells
por: Hughes-Parry, Hannah E., et al.
Publicado: (2019)

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
por: Ito, Yusuke, et al.
Publicado: (2022)

Engineering chimeric antigen receptor T cells for solid tumour therapy
por: Liu, Longwei, et al.
Publicado: (2022)

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma
por: Ogunnaike, Edikan A., et al.
Publicado: (2021)

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
por: Zhang, Peng, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
por: Martino, Massimo, et al.
Publicado: (2022)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Acute aluminium phosphide poisoning: Can we predict mortality?
por: Mathai, Ashu, et al.
Publicado: (2010)

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells
por: Zhuang, Xiaoxuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j9vsgk8sol93be2nlo26smagbr